Auris Medical To Announce Third Quarter 2016 Financial Results And Host Conference Call On Thursday, November 10, 2016

Basel, Switzerland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Zug, Switzerland, Nov. 3, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the third quarter of 2016 on Thursday, Nov. 10, 2016. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the Company's financial results and to provide a general business update.

To participate in this conference call, dial 1-877-280-3459 (USA) or +1-646-254-3373 (International), and enter passcode 6069780. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at A replay will be available approximately two hours following the live call.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the Phase 3 development of treatments for acute inner ear tinnitus (Keyzilen TM; AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."

Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350,

If you liked this article you might like

Auris Medical Stock Suring on AM-111 Fast Track Designation

5 Breakout Stocks Under $10 Set to Soar

Auris Medical (EARS) Stock Plummets on Clinical Trial Miss, Q2 Loss

5 Stocks Under $10 Set to Soar

3 Stocks Boosting The Drugs Industry Higher